Newsroom

February 2016

• Press release Feb 23, 2016

  Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration

  Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions…
• Press release Feb 23, 2016

  Novartis Aktionäre genehmigen alle Anträge des Verwaltungsrats

  Aktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des…
• 
  Story Feb 22, 2016 From Our Labs

  CRISPR genome editing fuels cancer drug discovery

  Genome editing advances drug discovery in biomedical research.

• Press release Feb 19, 2016

  Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)

  PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult…
• Press release Feb 18, 2016

  Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.

  Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma  The goal of MIGS is to reduce or…
• 
  Story Feb 14, 2016 Access to Healthcare

  Tailoring tactics to tackle chronic disease in low-income countries

  Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world.

• In The News Feb 12, 2016

  Joe Jimenez on how to improve healthcare

  In an op ed with Foreign Affairs, Joe Jimenez explains why outcomes, innovation and collaboration are the keys to improving healthcare worldwide.
• 
  Story Feb 12, 2016 From Our Labs

  Rediscovering the power of nature’s exquisite complexity

  Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research

• Press release Feb 12, 2016

  Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA

  Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU…
• 
  Story Feb 11, 2016 Discovery

  Intractable tumor cells crippled

  Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.

• Press release Feb 11, 2016

  Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

  Sandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
• 
  Story Feb 10, 2016 Discovery

  Leveraging the liver’s ability to heal scarred tissue

  A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.